Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Sees Strong Cholesterol Market In ‘04; Zocor Growth, Profit From Zetia

Executive Summary

Merck expects Zocor sales to remain in the $5 bil. range in 2004 despite generic erosion overseas and the introduction of new competitors in the cholesterol class

You may also be interested in...



Merck Raises Vioxx, Arcoxia Guidance; Ex-U.S. Sales Spur Growth

Merck is raising its 2004 sales guidance for its global COX-2 inhibitor business to the $2.8 bil.-$3 bil. range based on faster than expected growth for Vioxx and Arcoxia.

Merck Raises Vioxx, Arcoxia Guidance; Ex-U.S. Sales Spur Growth

Merck is raising its 2004 sales guidance for its global COX-2 inhibitor business to the $2.8 bil.-$3 bil. range based on faster than expected growth for Vioxx and Arcoxia.

Zetia/Zocor Market Will Be First-Line Patients, Not Switches, Merck Says

Merck/Schering's Zetia/Zocor fixed-dose combination will be positioned as a first-line, cholesterol-lowering therapy, while Zetiawill be reserved primarily for the niche population of patients who are not at their target cholesterol levels

Related Content

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel